Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease

Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease

Inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis is a chronic autoimmune disease affecting nearly five million people worldwide. Among all drug delivery system, oral administration is the most preferable route for colon-specific targeting and the treatment of IBD. Here...

Full description

Bibliographic Details
Main Authors: Hongzhi Qiao, Dong Fang, Jing Chen, Yuan Sun, Chen Kang, Liuqing Di, Junsong Li, Zhipeng Chen, Jun Chen, Yahan Gao
Format: Article
Language:English
Published: Taylor & Francis Group 2017-01-01
Series:Drug Delivery
Subjects:
curcumin polymer
colon-targeting
bacterial reduction
inflammatory bowel disease
oral administration
Online Access:http://dx.doi.org/10.1080/10717544.2016.1245367

Internet

http://dx.doi.org/10.1080/10717544.2016.1245367

Similar Items